1
|
de Matos PH, da Silva TP, Mansano AB, Gancedo NC, Tonin FS, Pelloso FC, Petruco MV, de Melo EB, Fernandez-Llimos F, Sanches ACC, de Mello JCP, Chierrito D, de Medeiros Araújo DC. Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review. Inflamm Res 2022; 71:1489-1500. [PMID: 36307652 PMCID: PMC9616414 DOI: 10.1007/s00011-022-01642-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 08/29/2022] [Accepted: 09/10/2022] [Indexed: 11/28/2022] Open
Abstract
Objective and design The current study aimed to summarize the evidence of compounds contained in plant species with the ability to block the angiotensin-converting enzyme 2 (ACE-II), through a scoping review. Methods PubMed and Scopus electronic databases were used for the systematic search and a manual search was performed Results Studies included were characterized as in silico. Among the 200 studies retrieved, 139 studies listed after the exclusion of duplicates and 74 were included for the full read. Among them, 32 studies were considered eligible for the qualitative synthesis. The most evaluated class of secondary metabolites was flavonoids with quercetin and curcumin as most actives substances and terpenes (isothymol, limonin, curcumenol, anabsinthin, and artemisinin). Other classes that were also evaluated were alkaloid, saponin, quinone, substances found in essential oils, and primary metabolites as the aminoacid l-tyrosine and the lipidic compound 2-monolinolenin. Conclusion This review suggests the most active substance from each class of metabolites, which presented the strongest affinity to the ACE-II receptor, what contributes as a basis for choosing compounds and directing the further experimental and clinical investigation on the applications these compounds in biotechnological and health processes as in COVID-19 pandemic. Supplementary Information The online version contains supplementary material available at 10.1007/s00011-022-01642-7.
Collapse
Affiliation(s)
- Pedro Henrique de Matos
- Centro Universitário Ingá-UNINGÁ, Rodovia PR 317, 6114. Parque Industrial, 200, Maringá,, PR, 87035-510, Brazil
| | - Thalita Prates da Silva
- Departamento de Farmácia, Universidade Estadual de Maringá, Avenida Colombo, Maringá, 5790, Brazil
| | - Amanda Benites Mansano
- Departamento de Farmácia, Universidade Estadual de Maringá, Avenida Colombo, Maringá, 5790, Brazil
| | - Naiara Cássia Gancedo
- Departamento de Farmácia, Universidade Estadual de Maringá, Avenida Colombo, Maringá, 5790, Brazil
| | - Fernanda Stumpf Tonin
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Paraná, Avenida Prefeito Lothário Meissner 632, Curitiba, Brazil
- H&TRC-Health & Technology Research Center, ESTeSL-Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, Portugal
| | - Fernando Castilho Pelloso
- Complexo Hospital de Clínicas, Universidade Federal Do Paraná, Rua General Carneiro, Curitiba, 181, Brazil
| | | | - Eduardo Borges de Melo
- Centro de Ciências Médicas e Farmacêuticas, Universidade Estadual do Oeste do Paraná, Rua Universitário 2069, Cascavel, Brazil
| | - Fernando Fernandez-Llimos
- Departamento de Ciências do Medicamento, Universidade do Porto, Praça Gomes Teixeira, Porto, Portugal
| | | | | | - Danielly Chierrito
- Centro Universitário Ingá-UNINGÁ, Rodovia PR 317, 6114. Parque Industrial, 200, Maringá,, PR, 87035-510, Brazil
| | | |
Collapse
|